Literature DB >> 15479812

Evidence for both lytic replication and tightly regulated human herpesvirus 8 latency in circulating mononuclear cells, with virus loads frequently below common thresholds of detection.

Elisa Martró1, Michael J Cannon, Sheila C Dollard, Thomas J Spira, A Scott Laney, Chin-Yih Ou, Philip E Pellett.   

Abstract

To address whether human herpesvirus 8 (HHV-8) DNA in peripheral blood mononuclear cells (PBMCs) might be the product of latent or lytic infection and to shed light on sporadic detection of HHV-8 DNA in individuals seropositive for the virus, we studied the frequency of infected cells, total virus load, and virus load per infected cell in PBMCs from men coinfected with HHV-8 and human immunodeficiency virus (HIV), some of whom had Kaposi's sarcoma. The low frequencies of infected cells detected (fewer than one per million cells in some individuals) suggest that the prevalence of the virus in circulating leukocytes was underestimated in previous studies that employed more conventional sampling methods (single, small-volume specimens). Mean virus loads ranged from 3 to 330 copies per infected PBMC; these numbers can represent much higher loads in individual lytically infected cells (>10(3) genomes/cell) in mixtures that consist predominantly of latently (relatively few genomes) infected cells. The presence in some subjects of high HHV-8 mean genome copy numbers per infected cell, together with viral DNA being found in plasma only from subjects with positive PBMCs, supports earlier suggestions that the virus can actively replicate in PBMCs. In some individuals, mean virus loads were less than 10 genomes per infected cell, suggesting a tightly controlled purely latent state. HHV-8 genome copy numbers are substantially higher in latently infected cells derived from primary effusion lymphomas; thus, it appears that HHV-8 is able to adopt more than one latency program, perhaps analogous to the several types of Epstein-Barr virus latency.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15479812      PMCID: PMC523251          DOI: 10.1128/JVI.78.21.11707-11714.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

Review 1.  Kaposi's sarcoma-associated herpesvirus: epidemiology, virology, and molecular biology.

Authors:  R Sarid; S J Olsen; P S Moore
Journal:  Adv Virus Res       Date:  1999       Impact factor: 9.937

2.  Human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) infection in men receiving treatment for HIV-1 infection.

Authors:  T B Campbell; L Fitzpatrick; S MaWhinney; X Zhang; R T Schooley
Journal:  J Acquir Immune Defic Syndr       Date:  1999-12-01       Impact factor: 3.731

3.  Quantitation of target molecules from polymerase chain reaction-based limiting dilution assays.

Authors:  A G Rodrigo; P C Goracke; K Rowhanian; J I Mullins
Journal:  AIDS Res Hum Retroviruses       Date:  1997-06-10       Impact factor: 2.205

Review 4.  Classic kaposi sarcoma: epidemiology and risk factors.

Authors:  J Iscovich; P Boffetta; S Franceschi; E Azizi; R Sarid
Journal:  Cancer       Date:  2000-02-01       Impact factor: 6.860

5.  HBV viral load within subpopulations of peripheral blood mononuclear cells in HBV infection using limiting dilution PCR.

Authors:  M Trippler; K H Meyer zum Büschenfelde; G Gerken
Journal:  J Virol Methods       Date:  1999-03       Impact factor: 2.014

6.  Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders.

Authors:  D T Rowe; L Qu; J Reyes; N Jabbour; E Yunis; P Putnam; S Todo; M Green
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

7.  Open reading frame 26 of human herpesvirus 8 encodes a tetradecanoyl phorbol acetate- and butyrate-inducible 32-kilodalton protein expressed in a body cavity-based lymphoma cell line.

Authors:  E O'Neill; J L Douglas; M L Chien; J V Garcia
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

8.  B cells regulate murine gammaherpesvirus 68 latency.

Authors:  K E Weck; S S Kim; I V Virgin HW; S H Speck
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

9.  Detection of Kaposi's sarcoma-associated herpesvirus in peripheral blood cells in human immunodeficiency virus infection: association with Kaposi's sarcoma, CD4 cell count, and HIV RNA levels.

Authors:  J Min; D A Katzenstein
Journal:  AIDS Res Hum Retroviruses       Date:  1999-01-01       Impact factor: 2.205

10.  Human herpesvirus 8 DNA load in leukocytes of human immunodeficiency virus-infected subjects: correlation with the presence of Kaposi's sarcoma and response to anticytomegalovirus therapy.

Authors:  G Boivin; A Gaudreau; E Toma; R Lalonde; J P Routy; G Murray; J Handfield; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

View more
  10 in total

1.  Human herpesvirus 8 load and progression of AIDS-related Kaposi sarcoma lesions.

Authors:  Martin M Nsubuga; Robert J Biggar; Susan Combs; Vickie Marshall; Georgina Mbisa; Fred Kambugu; Meghna Mehta; Benon Biryahwaho; Charles S Rabkin; Denise Whitby; Sam M Mbulaiteye
Journal:  Cancer Lett       Date:  2008-01-30       Impact factor: 8.679

2.  Four-antigen mixture containing v-cyclin for serological screening of human herpesvirus 8 infection.

Authors:  Peter D Burbelo; Hannah P Leahy; Sandra Groot; Lisa R Bishop; Wendell Miley; Michael J Iadarola; Denise Whitby; Joseph A Kovacs
Journal:  Clin Vaccine Immunol       Date:  2009-03-04

Review 3.  Multicentric Castleman's disease: a challenging diagnosis.

Authors:  Györgyi Műzes; Ferenc Sipos; Judit Csomor; Lídia Sréter
Journal:  Pathol Oncol Res       Date:  2013-03-21       Impact factor: 3.201

4.  Simultaneous quantification of human herpesvirus 8 DNA by real time PCR in different tissues of HIV infected cuban patients with Kaposi's sarcoma.

Authors:  Vivian Kourí; Pedro A Martínez; Orestes Blanco; Virginia Capó; María E Rodríguez; María Del C Dovigny; Lidia Cardellá; Angela Gala; Narciso A Jiménez; Consuelo Correa; Yoan Alemán; Lissette Pérez; Alina Álvarez; Ulrich Hengge
Journal:  Herpesviridae       Date:  2010-12-07

5.  Non-detection of human herpesvirus 8 (HHV-8) DNA in HHV-8-seropositive blood donors from three Brazilian regions.

Authors:  José Eduardo Levi; Maria Claudia Nascimento; Laura Masami Sumita; Vanda Akico Ueda Fick de Souza; Wilton S Freire; Philippe Mayaud; Claudio S Pannuti
Journal:  PLoS One       Date:  2011-08-08       Impact factor: 3.240

Review 6.  Human herpesvirus 8--a novel human pathogen.

Authors:  Daniel C Edelman
Journal:  Virol J       Date:  2005-09-02       Impact factor: 4.099

7.  Human herpesvirus 8 induces polyfunctional B lymphocytes that drive Kaposi's sarcoma.

Authors:  Emilee R Knowlton; Giovanna Rappocciolo; Paolo Piazza; Lauren M Lepone; Sagar V Nadgir; Arlene Bullotta; Stella J Berendam; Jun Li; Todd A Reinhart; Frank J Jenkins; Charles R Rinaldo
Journal:  mBio       Date:  2014-09-02       Impact factor: 7.867

8.  Measurements of human herpesvirus 8 viral load in blood before and after leukoreduction filtration.

Authors:  Sheila C Dollard; John D Roback; Clifford Gunthel; Minal M Amin; Sheilagh Barclay; Ericka Patrick; Matthew J Kuehnert
Journal:  Transfusion       Date:  2013-01-30       Impact factor: 3.157

9.  Rapid Multiplexed Immunoassay for Detection of Antibodies to Kaposi's Sarcoma-Associated Herpesvirus.

Authors:  Cathy Logan; Kathryn Todorof; Suzanne P Fiorillo; Thomas B Campbell; John H Elder; Margaret Borok; Ivy Gudza; Lovemore Gwanzura; Buxton Ndemera; Michael J Lochhead; Constance A Benson; Robert T Schooley
Journal:  PLoS One       Date:  2016-09-26       Impact factor: 3.240

10.  Production of antibody against elephant endotheliotropic herpesvirus (EEHV) unveils tissue tropisms and routes of viral transmission in EEHV-infected Asian elephants.

Authors:  Varankpicha Kochagul; Saralee Srivorakul; Kittikorn Boonsri; Chalermchart Somgird; Nattawooti Sthitmatee; Chatchote Thitaram; Kidsadagon Pringproa
Journal:  Sci Rep       Date:  2018-03-16       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.